Low BCL7A expression predicts poor prognosis in ovarian cancer

J Ovarian Res. 2019 May 10;12(1):41. doi: 10.1186/s13048-019-0518-0.

Abstract

Background and objective: Ovarian cancer is a common gynaecological cancer with a poor prognosis that poses a serious threat to human life and health. It is essential to explore the possible prognostic biomarkers of ovarian cancer. As an important tumour suppressor gene, BCL7A actively participates in the growth of tumours. We aimed to study the prognostic role of BCL7A in ovarian cancer.

Results: Through data mining of RNAseq data from the Cancer Genome Atlas database (TCGA), we explored the clinical relevance of BCL7A mRNA expression. As a result, we found that BCL7A is expressed at low levels in ovarian cancer tissues and is correlated with survival status. Survival analysis showed that, compared with those who had higher levels of BCL7A expression, patients with ovarian cancer and low levels of BCL7A generally had shorter overall/relapse-free survival times. Cox regression models showed that low BCL7A expression could be used as an independent prognostication factor for ovarian cancer patients.

Conclusions: Low BCL7A expression is an independent risk factor for poor prognosis in ovarian cancer patients.

Keywords: BCL7A; Data mining; Ovarian cancer; Prognosis.

MeSH terms

  • Female
  • Humans
  • Microfilament Proteins / biosynthesis*
  • Microfilament Proteins / genetics
  • Middle Aged
  • Neoplasm Staging
  • Oncogene Proteins / biosynthesis*
  • Oncogene Proteins / genetics
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / mortality
  • Ovarian Neoplasms / pathology
  • Prognosis
  • RNA, Messenger / metabolism
  • Risk Factors
  • Survival Analysis

Substances

  • BCL7A protein, human
  • Microfilament Proteins
  • Oncogene Proteins
  • RNA, Messenger